A Real-World Study on the Effect of Imrecoxib for Patients with Axial Spondyloarthritis

PURPOSE: Non-steroidal anti-inflammatory drugs (NSAIDs) have generally been viewed as first-line therapy for axial spondyloarthritis (axSpA). Imrecoxib is a selective COX-2 inhibitor developed independently in China. At present, only one single-center RCT trial has shown that imrecoxib is equally ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Zong, He-xiang, Xu, Sheng-qian, Wang, Jian-xiong, Chu, Yi-ran, Chen, Ke-ming, Wang, Cong, Tong, Wan-qiu, Wang, Xi-le
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416422/
https://www.ncbi.nlm.nih.gov/pubmed/36033132
http://dx.doi.org/10.2147/DDDT.S376406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416422/
https://www.ncbi.nlm.nih.gov/pubmed/36033132
http://dx.doi.org/10.2147/DDDT.S376406

Ejemplares similares